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[57] ABSTRACT 
Substituted isocoumarins, their use in inhibiting serine 
proteases with chymotrypsin-like and elastase-like spec-
ificity and their roles as anti-inflammatory agents. 
1,5 Claims, No Drawings 
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SUBSTITUTED ISOCOUMARINS 
STATEMENT OF GOVERNMENT INTEREST 
similar amino acids. Chymotrypsin and chymotrypsin-
like enzymes hydrolyze peptide bonds where P1 amino 
acid is Trp, Tyr, Phe, Met, Leu or other amino acid 
residues which contain aromatic or large alkyl side 
This invention was made with government support 
under Contract No. HL34035 and HL29307 awarded 
by the National Institutes of Health, National Heart, 
Lung and Blood Institute. The government has certain 
rights in the invention. 
5 chains. All of the above enzymes have extensive sec-
ondary specificity and recognize amino acid residues 
removed from the P1 residue. 
It is an object of this invention to discover new prote-
ase inhibitors, especially elastase inhibitors, and chy-
This is a continuation-in-part of copending applica-
tions Ser. Nos. 215,994 filed on July 7, 1988 now aban-
doned, 374,980 filed on July 3, 1989 now U.S. Pat. No. 
4,954,519, issued Sep. 4, 1990. 
BACKGROUND OF THE INVENTION 
10 mase inhibitors. These inhibitors are useful for control-
ling tissue damage and various inflammatory conditions 
mediated by proteases particularly elastases. The inhibi-
tors of this invention would also be useful for control-
ling hormone processing by serine proteases and for 
15 treating diseases related to tryptases and chymases such 
as inflammation and skin blistering. 1. Field of the Invention 
This invention relates to a novel class of heterocyclic 
compounds useful for selectively inhibiting chymotryp-
sin-like enzymes, selectively inhibiting elastase or for 
generally inhibiting serine proteases of all classes. This 20 
invention also relates to a method of treating inflamma-
tion in patients using the novel compounds of the pres-
ent invention. We have found that isocoumarins substi-
tuted with hydrophobic groups are potent inhibitors of 
chymases and elastase, therefore they are useful as anti- 25 
inflammatory agents. 
2. Description of the Related Art 
Serine proteases play critical roles in several physio-
logical processes such as digestion, blood coagulation, 
complement activation, fibrinolysis, viral infection, fer- 30 
tilization, and reproduction. Serine proteases are not 
only a physiological necessity, but also a potential ha-
zard if they are not controlled. Uncontrolled proteolysis 
by elastases may cause pancreatitis, emphysema, rheu-
matoid arthritis, bronchial inflammation and adult respi- 35 
ratory distress syndrome. Human polymorphonuclear 
leukocyte elastase may also be involved in blistering. 
Accordingly, specific and selective inhibitors of these 
proteases should be potent anti-inflammatory agents 
useful in the treatment of protease-related diseases 40 
(Powers and Harper, in Proteinase Inhibitors, Barrett 
and Salvesen, eds., Elsevier, 1986, pp 55-152, incorpo-
rated herein by reference). In vitro proteolysis by chy-
motrypsin or the elastase family is a serious problem in 
the production, purification, isolation, transport or stor- 45 
age of peptides and proteins. 
Anti-inflammatory agents were used to treat elas-
tases-associated inflammation iJ!cluding rheumatoid 
arthritis and emphysema. Although the naturally occur-
ring protease inhibitor, al-protease inhibitor (al-PI) 50 
has been used to treat patients with emphysema, this 
inhibitor is not widely used clinically due to the high 
dosage needed for the treatment and difficulty of pro-
ducing large quantities. Therefore small molecular 
weight elastase inhibitors are needed for therapy. 55 
SUMMARY OF THE INVENTION 
It is an object of this invention to find a novel group 
of specific inhibitors for elastase, chymotrypsin and 
other serine proteases of similar substrate specificity and 60 
for serine proteases in general. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of 
the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 
amino acid residue on the carbonyl side of the split bond 65 
(P1 residue) is Lys or Arg. Elastase and elastase-like 
enzymes, on the other hand, cleave peptide bonds 
where the P1 amino acid is Ala, Val, Ser, Leu and other 
It is a further object of this invention to find a novel 
group of specific inhibitors useful in vitro for inhibiting 
trypsin, elastase, chymotrypsin and other serine pro-
teases of similar specificity and for inhibiting serine 
proteases in general. Such inhibitors could be used to 
identify new proteolytic enzymes encountered in re-
search. They could also be used in research and indus-
trially to prevent undesired proteolysis that occurs dur-
ing the production, isolation, purification, transport and 
storage of valuable peptides and proteins. Such proteo-
lysis often destroys or alters the activity and/or func-
tion of the peptides and proteins. Uses would include 
the addition of the inhibitors to antibodies, enzymes, 
plasma proteins, tissue extracts or other proteins and 
peptides which are widely sold for use in clinical analy-
ses, biomedical research, and for many other reasons. 
For some uses a specific inhibitor would be desirable, 
while in other cases, an inhibitor with general specific-
ity would be preferred. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Isocoumarins substituted with hydrophobic groups 
have been found to be excellent inhibitors of several 
serine proteases including human leukocyte elastase, 
porcine pancreatic elastase, bovine chymotrypsin and 
human leukocyte cathepsin G. These compounds in-
hibit the serine proteases by reaction with the active site 
serine to form an acyl enzyme, which in some cases may 
further react with another active site nucleophile to 
form an additional covalent bond. These structures may 
be used in vivo to treat diseases such as emphysema, 
adult respiratory distress syndrome, rheumatoid arthri-
tis and pancreatitis which result from uncontrolled pro-
teolysis by elastase, chymotrypsin, trypsin and related 
serine proteases. These inhibitors may be used in vitro 
to prevent proteolysis which occurs in the process of 
production, isolation, purification, storage or transport 
of peptid!!S and proteins. The novel substituted 
isocoumarin and related heterocyclic compounds have 
the following structural formula: 
0 
RlfYl~ 
~z 
y 
or a pharmaceutically acceptable salt, wherein 
(I) 
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Z is methoxy, 
4 
group substituted with J, or C1-6 alkyl with two at-
tached phenyl groups substituted with J, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl substi-
R is selected from the group consisting of O=C-
=N-, S==C=N-, M-NH-, M-AA-NH-, 
M-AA-AA-NH-, M-0-, M-AA-0, 
M-AA-AA-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, X-N-
H-S02-, X-CS-, X-S02-, X-0-CO-, 
X-0-CS-, or D-CO-, 
5 tuted with K, 9-fluorenyl, phenyl, phenyl substituted 
with J, phenyl disubstituted with J, phenyl trisubstitu-
ted with J, naphthyl, naphthyl substituted with J, naph-
thyl disubstituted with J, naphthyl trisubstituted with J, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, IO 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl substi-
tuted with K, 9-fluoroenylmethyl, phenyl, phenyl sub-
stituted with J, phenyl disubstituted with J, phenyl 
trisubstituted with J, naphthyl, naphthyl substituted 
with J, naphthyl disubstituted with J, naphthyl trisubsti- 15 
tuted with J, C1-6alkyl with an attached phenyl group, 
C1-6 alkyl with two attached phenyl groups, C1-6 alkyl 
with an attached phenyl group substituted with J, or 
C1-6 alkyl with two attached phenyl groups substituted 
w~J, W 
wherein D represents C1-6 fluoroalkyl, C1-6 alkyl 
substituted with K, C1-6 fluoroalkyl substituted with K, 
9-fluorenylmethyl, phenyl, phenyl substituted with J, 
phenyl disubstituted with J, phenyl trisubstituted with 25 J, naphthyl, naphthyl substituted with J, naphthyl di-
substituted with J, naphthyl trisubstituted with J, C1-6 
alkyl with an attached phenyl group substituted with J, 
or C1-6 alkyl with two attached phenyl groups substi-
tuted with J, 30 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 al-
kyl-0-CO-NH-, or C1-6 alkyl-S~, 
wherein K represents halogen, COOH, OH, CN, 35 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 dialkyla-
mine, C1-6 alkyl-0-CO-, or C1-6 al-
kyl-0-CO-NH, C1-6 alkyl-S-, or tosylamino, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, tryptophan, 40 
glycine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine 45 
or sarcosine, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compound are represented by structure (I) 50 
where, 
Z is ethoxy, 
wherein R is selected from the group consisting of 
O==C=N-, S==C=N-, M-NH-, 
M-AA-NH-, M-AA-AA-NH-, M-0-, 55 
M-AA-0, M-AA-AA-0-, 
wherein M represents NH2-CS-, NH2-S02-, 
L-NH-CO-, X-NH-CS-, X-NH-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, or 
X-0-CS-, 60 
wherein L represents C1-6 fluoroalkyl, C1-6 alkyl 
substituted with K, C1-6 fluoroalkyl substituted with K, 
9-fluorenylmethyl, phenyl substituted with J, phenyl 
disubstituted with J, phenyl trisubstituted with J, naph-
thyl, naphthyl substituted with J, naphthyl disubstituted 65 
with J, naphthyl trisubstituted with J, C1-6 alkyl with an 
attached phenyl group, C1-6 alkyl with two attached 
phenyl groups, C1-6 alkyl with an attached phenyl 
C1-6 alkyl with an attached phenyl group, C1-6 alkyl 
with two attached phenyl groups, C1-6 alkyl with an 
attached phenyl group substituted with J, or C1-6 alkyl 
with two attached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 al-
kyl-0-CO-NH-, or C1-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 dialkyla-
mine, C1-6 alkyl-0-CO-, or C1-6 al-
kyl-0-CO-NH, C1-6 alkyl-S-, or tosylamino, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine 
or sarcosine, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compound are represented by structure (I) 
where, 
Z is selected from the group consisting of propoxy, 
C1-6 alkoxy with a phenyl group attached to the C1-6 
alkoxy group, C1-6 alkyl with a phenyl group attached 
to the C1-6 alkyl, C1-6 alkoxy with an attached phenyl 
group substituted with J, C1-6 alkyl with an attached 
phenyl group substituted with J, 
wherein R is selected from the group consisting of 
O==C=N-, . S==C=N-, M-NH-, 
M-AA-NH-, M-AA-AA-NH-, M-0-, 
M-AA-0, M-AA-AA-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, X-N-
H-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl substi-
tuted with K, 9-fluorenylmethyl, phenyl, phenyl substi-
tuted with J, phenyl disubstituted with J, phenyl trisub-
stituted with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstituted 
with J, C1-6 alkyl with an attached phenyl group, C1-6 
alkyl with two attached phenyl groups, C1-6 alkyl with 
an attached phenyl group substituted with J, or C1-6 
alkyl with two attached phenyl groups substituted with 
J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 al-
kyl-0-CO-NH-, or Ct-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1~6 alkoxy, Ct-6 alkylamine, Ct-6 dialkyla-
mine, Ct-6 alkyl-0-CO-, or Ct-6 al-
kyl-0-CO-NH, Ct-6 alkyl-S-, or tosylamino, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, tryptophan, 
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phenyl group substituted with J, Ct-6 alkoxy with an 
attached phenyl group disubstituted with J, 
glycine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine 
or sarcosine, and 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, Ct-6 alkyl, Ct-6 alkoxy, Ct-6 alkylamine, C1-6 
5 dialkylamine, C1-6 alkyl-0-CO-, Ct-6 al-
kyl-0-CO-NH-, or Ct-6 alkyl-S-, 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Ct-6 alkoxy, Ct-6 alkylamine, Ct-6 dialkyla-
mine, Ct-6 alkyl-0-CO-, or Ct-6 al-Alternately the novel isocoumarin and related heter-
ocyclic compound are represented by structure (I) 
where, 
10 kyl-0-CO-NH-, Ct-6 alkyl-S-, or tosylamino, 
R is biotin-spacer-T, 
wherein T represents -NH-, -0-, or -S-, 
wherein spacer represents -[NH-(CH2)n-CO]n-, 
-[NH-(CH2)n-NH-CO]n-, -[NH-C6-
wherein Z is selected from the group consisting of 
Ct-6 alkoxy with a halogen attached to the alkoxy 
group, Ct-6 alkyl with a halogen attached to the alkyl 
group, Ct-6 alkoxy with an attached Ct-6 alkoxy group 
substituted with Q, 
wherein Q represents H, or Ct-6 alkoxy, 
R is selected from the group consisting of OH, NH2, 
15 R4-CO]n-, -[NH-~-NH-CO]n-, -N-
H-(CH2)n-CO-NH-(CH2)n-NH-CO-, -N-
H-(CH2)n-CO-NH-(CH2)3-NH-(CH2)3-N-
H-CO-CH2CH2-CO-, or -(AA)n-, where 
N02, O=C=N-, S=C=N-, AA-NH-, 
AA-AA-NH, AA-0-, AA-AA-0-, 20 
M-NH-, M-AA-NH-, M-AA-AA-NH-, 
M-0-, M-AA-0, M-AA-AA-0-, 
n=l-6. 
wherein AA represents alanine, valine, leucine, iso-
leucine, praline, methionine, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
wherein AA represents alanine, valine, leucine, iso-
leucine, praline, methionine, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, beta-alanine, norleucine, norvaline, 
phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine 
or sarcosine, 
25 phenylglycine, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, ornithine 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-CS-, NH2-S02-, X-NH-CO-, X-N-
H-CS-, X-NH-S02-, X-CO-, X-CS-, 
X-S02-, X,--0-CO-, or X-0-CS-, 
30 
wherein X represents Ct-6 alkyl, Ct-6 fluoroalkyl, 35 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl substi-
tuted with K, phenyl, phenyl substituted with J, phenyl 
disubstituted with J, phenyl trisubstituted with J, naph-
thyl, naphthyl substituted with J, naphthyl disubstituted 
with J, naphthyl trisubstituted with J, C1-6alkyl with an 40 
attached phenyl group, C1-6 alkyl with two attached 
phenyl groups, Ct-6 alkyl with an attached phenyl 
group substituted with J, or C1-6 alkyl with two at-
tached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 45 
NH2, Ct-6 alkyl, Ct-6 alkoxy, Ct-6 alkylamine, Ct-6 
dialkylamine, Ct-6 alkyl-0-CO-, C1-6 al-
kyl-0-CO-NH-, or Ct-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Ct-6 alkoxy, C1-6 alkylamine, Ct-6 dialkyla- 50 
mine, Ct-6 alkyl-0-CO-, or Ct-6 al-
kyl-0-CO-NH-, Ct-6 alkyl-S-, or tosylamino, 
and 
or sarcosine, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
The compounds of Formula (I) can also contain one 
or more substituents at position B as shown in the fol-
lowing structure: 
wherein electronegative substituents such as N02, CN, 
Cl, COOR, and COOH will increase the reactivity of 
the isocoumarin, and electropositive substituents such 
as NH2, OH, alkoxy, thioalkyl, alkyl, alkylamino, and 
dialkylamino will increase its stability. Neutral substitu-
ents could also increase the stability of acyl enzyme and 
improve the effectiveness of the inhibitors. 
Other substituted isocoumarins have been prepared 
earlier for other purposes (illustrative examples: 3-
chloroisocoumarin, Davies and Poole, J. Chem. Soc., 
pp 1616-1629 (1928); 3-chloro and 3,4-
dichloroisocoumarin, Milevskaya, Belinskaya, and 
Yagupol'skii, Zhur. Org. Khim. 9, pp 2145-2149 (1973); Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Alternately the novel isocoumarin and related heter-
ocyclic compounds are represented by structure (I) 
where, 
55 3-methyl and 4-carboxy-3-methylisocoumarin, Tirod-
kar and Usgaonkar, Ind. J. Chem. 7, pp 1114-1116 
(1969); 7-nitro and 7-aminoisocoumarin, Choksey and 
Usgaonkar, Ind. J. Chem. 14B, pp 596-598 (1976), the 
Z is selected from the group consisting ofH, halogen, 
Ct-6 alkyl, C1-6 fluorinated alkyl, C1-6 alkyl substituted 60 
with K, Ct-6 fluorinated alkyl substituted with K, Ct-6 
alkoxy, Ct-6 fluorinated alkoxy, Ct-6 alkoxy substituted 
with K, Ct-6 fluorinated alkoxy substituted with K, 
Ct-6 alkyl with a phenyl group attached to the alkyl 
group, Ct-6 alkoxy with a phenyl group attached to the 65 
alkoxy group, C1-6alkyl with an attached phenyl group 
substituted with J, C1-6 alkyl with an attached phenyl 
group disubstituted with J, C1-6alkoxy with an attached 
preceding articles are incorporated herein by refer-
ence). 
A number of other substituted isocoumarins have 
been prepared recently for inhibition of serine proteases 
(3-chloroisocoumarin, Harper, Hemmi, and Powers, J. 
Am. Chem. Soc. 105, pp 6518-6520 (1983); 3,4-
dichloroisocoumarin, Harper, Hemmi, and Powers, 
Biochemistry 24, pp 1831-1841 (1985); 3-alkoxy-7-
amino-4-chloroisocoumarin, Harper and Powers, J. 
Am. Chem. Soc. 106, pp 7618-7619 (1984), Harper and 
7 
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7-benzylthiocarbamoylamino-4-chloro-3-propylox-
yisocoumarin 
7-(m-nitrobenzoyl)amino-4-chloro-3-propylox-
yisocoumarin 
5 7-[ (2-thiomethyl)acetyl)amino-4-chloro-3-propylox-
Powers, Biochemistry 24, 7200-7213 (1983); substituted 
isocoumarins with basic groups (aminoalkoxy, 
guanidino or isothiureidoalkoxy), Kam, Fujikawa and 
Powers, Biochemistry 27, pp 2547-2557 (1988); 7-sub-
stituted 3-alkoxy-4-chloroisocoumarins, Powers, Kam, 
Narasimhan, Oleksyszyn, Hernandez and Ueda, J. Cell 
Biochem. 39, pp 33-46 (1989), Powers, Oleksyszyn, 
Narasimhan, Kam, Radhakrishnan and Meyer, Jr. Bio-
chemistry 29, 3108-3118 (1990), the preceding articles 
are incorporated herein by reference; Powers and Har- 10 
per, U.S. Pat. No. 4,596,822; Powers and Kam, U.S. Pat. 
No. 4,845,242 which are also incorporated by refer-
ence). 
yisocoumarin 
7-(N-t-butyloxycarbonyl-valyl)amino-4-chloro-3-
propyloxyisocoumarin 
7-biotinylamino-4-chloro-3-propyloxyisocoumarin 
7-biotinylamino-4-chloro-3-(2-phenylethoxy)isocouma-
rin 
7-(6-biotinylaminocaproyl)amino-4-chloro-3-ethox-
yisocoumarin 
7-(6-biotinylaminocaproyl)amino-4-chloro-3-propylox-
yisocoumarin 
7-(6-biotinylaminocaproyl)amino-4-chloro-3-(2-
phenylethoxy)isocoumarin 
7-nitro-4-chloro-3-(2-bromoethoxy )isocoumarin 
7-amino-4-chloro-3-(2-bromoethoxy )isocoumarin 
The following compounds are representative of the 
invention: 15 
7-isocyanato-4-chloro-3-methoxyisocoumarin 
7-ethoxycarbonylamino-4-chloro-3-methoxyisocouma-
rin 
7-phenoxycarbonylamino-4-chloro-3-methox-
yisocoumarin 
7-benzyloxycarbonylamino-4-chloro-3-methox-
yisocoumarin 
7-carbamoy lamino-4-chloro-3-methoxyisocoumarin 
7-methylcarbamoylamino-4-chloro-3-methox-
yisocoumarin 
7-ethylcarbamoylamino-4-chloro-3-methoxyisocouma-
rin 
7-isopropylcarbamoylamino-4-chloro-3-methox-
yisocoumarin 
7-t-butylcarbamoylamino-4-chloro-3-methox-
yisocoumarin 
7-phenylcarbamoylamino-4-chloro-3-methox-
20 7-t-butylcarbamoylamino-4-chloro-3-(2-bromoethox-
y )isocoumarin 
7-isopropylcarbamoylamino-4-chloro-3-(2-bromoe-
thoxy )isocoumarin 
7-phenylcarbamoylamino-4-chloro-3-(2-bromoethox-
y )isocoumarin 
7-benzylcarbamoylamino-4-chloro-3-(2-bromoethox-
y )isocoumarin 
7-(R-a-methylbenzyl)carbamoylamino-4-chloro-3-(2-
bromoethoxy )isocoumarin 
25 
30 7-(S-a-methylbenzyl)carbamoylamino-4-chloro-3-(2-
bromoethoxy )isocoumarin 
7-naphthylcarbamoylamino-4-chloro-3-(2-bromoethox-
y )isocoumarin 
7-t-butylacetylamino-4-chloro-3-(2-bromoethox-
y)isocoumarin 
7-phenylacetylamino-4-chloro-3-(2-bromoethox-
yisocoumarin 
7-(N-benzyl-N-phenylethylcarbamoyl)amino-4-chloro- 35 
3-methoxyisocoumarin 
7-heptafluorobutyroylamino-4-chloro-3-methox-
yisocoumarin 
7-(9-fluorenylmethoxycarbonyl)amino-4-chloro-3-
methoxyisocoumarin 
7-(N-tosyl-a-phenylglycyl)amino-4-chloro-3-methox-
yisocoumarin 
y )isocoumarin 
7-(N-t-butyloxycarbonyl-D-phenylalanyl)amino-4-
chloro-3-(2-bromoethoxy)isocoumarin 
40 7-(N-t-butyloxycarbonyl-L-phenylalanyl)amino-4-
chloro-3-(2-bromoethoxy)isocoumarin 
7-(N-t-butyloxycarbonyl-L-alanylalanyl)amino-4-
chloro-3-(2-bromoethoxy)isocoumarin 
7-dansylamino-4-chloro-3-(2-bromoethoxy)isocoumarin 
45 7-phenylthiocarbamoylamino-4-chloro-3-(2-bromoe-
thoxy )isocoumarin 
7-(m-carboxyphenyl)thiocarbamoylamino-4-chloro-3-
(2-bromoethoxy )isocoumarin 
7-(p-carboxyphenyl)thiocarbamoylamino-4-chloro-3-
7-( o-phthalyl)amino-4-chloro-3-methoxyisocoumarin 
7-(o-methoxyphthalyl)amino-4-chloro-3-methox-
yisocoumarin 
7-methoxysuccinylamino-4-chloro-3-methox-
yisocoumarin 
7-methoxyglutarylamino-4-chloro-3-methoxyisocouma-
rin 
7-(3-phenylglutaryl)amino-4-chloro-3-methox-
yisocoumarin 
7-(m-methoxycarbonylaminobenzoyl)amino-4-chloro-
3-methoxyisocoumarin 
7-ethoxycarbonylamino-4-chloro-3-ethoxyisocoumarin 
7-ethylthiocarbamoylamino-4-chloro-3-ethox-
yisocoumarin 
7-phenylthiocarbamoylamino-4-chloro-3-ethox-
yisocoumarin 
7-dihydrocinnamoylamino-4-chloro-3-propylox-
yisocoumarin 
7-ethoxycarbonylamino-4-chloro-3-propylox-
yisocoumarin 
7-ethylcarbamoylamino-4-chloro-3-propylox-
yisocoumarin 
7-phenylcarbamoylamino-4-chloro-3-propylox-
yisocoumarin 
7-phenylthiocarbamoylamino-4-chloro-3-propylox-
yisocoumarin 
50 (2-bromoethoxy )isocoumarin 
7-nitro-4-chloro-3-(3-bromopropoxy )isocoumarin 
7-amino-4-chloro-3-(3-bromopropoxy )isocoumarin 
7-phenylcarbamoylamino-4-chloro-3-(3-bromopropox-
y )isocoumarin 
55 7-benzylcarbamoylamino-4-chloro-3-(3-bromopropox-
y )isocoumarin 
7-acetylamino-4-chloro-3-(3-bromopropoxy)isocouma-
rin 
7-phenylacetylamino-4-chloro-3-(3-bromopropox-
60 y)isocoumarin 
7-dihydrocinnamoylamino-4-chloro-3-(3-bromo-
propoxy)isocoumarin 
7-(N-t-butyloxycarbonyl-D-phenylalanyl)amino-4-
chloro-3-(3-bromopropoxy )isocoumarin 
65 7-(N-t-butyloxycarbonyl-L-phenylalanyl)amino-4-
chloro-3-(3-bromopropoxy)isocoumarin 
7-nitro-4-chloro-3-(2-bromoisopropoxy)isocoumarin 
7-amino-4-chloro-3-(2-bromoisopropoxy )isocoumarin 
9 
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7-amino-4-chloro-3-(2-methoxy)ethoxyisocoumarin 
7-amino-4-chloro-3-[2-(2-methoxyethoxy)ethox-
y ]isocoumarin 
It has been found that compounds of Formula (I) 
have anti-inflammatory activity and can be used to treat 5 
and control emphysema, adult respiratory distress syn-
drome and rheumatoid arthritis as shown in Table I, Ill, 
IV and .VII by effective inhibition of the proteolytic 
function of human leukocyte elastase and human ca-
thepsin G. Compounds of Formula (I) are effective in 10 
the theraputic use for pancreatitis by inhibiting the pro-
teolytic function of chymotrypsin and pancreatic elas-
tase as shown in Table I, II, III, IV and VII. Com-
pounds of Formula (I) are also effective in the preven-
tion of unnecessary proteolysis caused by chymotrypsin 15 
and elastase in the process of purification, transport and 
storage of peptides and proteins as shown in Table I, II, 
III, IV and VII by effective inhibition of chymotrypsin 
and elastase. 
Compounds of Formula (I) with a R group consisting 20 
of biotinylamino or an alkanoylamino with bi-
otinylamino group attached to alkanoylamino, Y group 
of Cl, and Z group of phenylethoxy group are effective 
in the inhibition of rat granule chymase as shown in 
Table V. The reactivation of inhibited rat granule chy- 25 
mase by these biotin isocoumarins in the presence of 
hydroxylamine as shown in Table VI is useful in the 
purification of these enzymes from rat granules by ap-
plying the inhibited granules to the avidin beads, where 
the biotinylated enzymes form tight complex with avi- 30 
din and retain on the column. Finally the enzyme can be 
reactivated and eluated out with hydroxylamine solu-
tion. The tight complex ofbiotin-avidin has been used as 
a powerful tool for purifying proteins. One such an 
example was shown by Williams et al., J. Biol. Chem. 35 
264, pp 7S36-7S4S (1989). The biotinylated-e-
aminocaproyl-peptide chloromethylketone was used to 
react with an active protease to form the biotinylated 
inactivated enzyme which retained on the avidin beads. 
This procedure allows removal of the protease from 40 
enzyme and zymogen mixture. 
Although little information is available on the struc-
ture of biotin binding site of avidin, the spacer between 
the biotin and the ligand molecule such as isocoumarin, 
chloromethyl ketone or insulin is crucial for the binding 45 
of biotinylated ligand to avidin. Green et al. (Biochem. 
J. 12S, pp 781-791 (1971)) attempted to determine the 
depth of the biotin binding site on avidin by studying 
the effect of chain length of w-bis(biotinyldiamines) on 
avidin polymer formation. He concluded that since 50 
stable polymers were formed when the chain linking the 
carboxyl groups of the biotins was 18 A long, the car-
boxyl group must lie about 8-9 A beneath the surface of 
the avidin molecule. Finn et al. (Biochemistry 23, pp 
2SS4-2SS8 (1984)) also calculated that the distance be- 55 
tween the carboxyl group of dethiobiotin and the N-ter-
minal amino group of the insulin B-chain would be 9.77 
A for dethiobiotinyl-Al-insulin, 18.36 A for dethiobioti-
nyl-A2-insulin, and 2S.S2 A for dethiobiotinyl-Al-
DPA-insulin (Al, A2, and Al-DPA were different 60 
chain length of spacer). Thus, any of these ligands 
should have sufficient space between the dethiobiotinyl 
and insulin portions to bind normally to avidin. How-
ever, only the longest of the three ligands showed the 
same rate of dissociation from Suc-avidin as dethiobio- 65 
tin itself. Therefore, spacer arms are required for opti-
mizing the interaction between the biotinylated ligand 
and the avidin complex. 
The biotin-avidin interaction is very useful in many 
areas such as immunoassays, receptor studies, im-
munocytochemical staining and protein isolation. In the 
enzyme immunoassay system, the biotinylated antibody 
is bound to the immobilized antigen or primary anti-
body, and avidin can be conjugated with enzymes, 
fluorochromes, ferritin or colloidal markers. The biotin-
avidin interaction can also be used in blotting tech-
niques for detecting proteins. It is very useful in the 
staining of cellular antigenic determinants. A wide vari-
ety of biotinylated primary probes such as monoclonal 
antibodies, lectins, vitamins, sugars, hormones and lipo-
proteins have been used. This specific interaction has 
also been used successfully in the selective retrieval of 
labelled plasma membrane components (Orr, J. Biol. 
Chem. 2S6, pp 761-766 (1981)). Biotinylated protein can 
be used as probes of protein structure and protein-
protein interaction (Billingsley et al. Biotechniques S, 
pp 22-31 (1987)). 
Inactivation rates of serine proteases by substituted 
isocoumarins were measured by the incubation method. 
An aliquot of inhibitor (2S or SO µl) in Me2SO was 
added to a buffered enzyme solution (0.01-2.3 µM) to 
initiate the inactivation. Aliquots (SO µl) were with-
drawn at various intervals and the residual enzymatic 
activity was measured. Me2SO concentration in the 
reaction mixture was 8-12% (v/v). O.lM Hepes, O.SM 
NaCl, pH 7.S buffer was utilized for the assays of all 
serine proteases. The inhibitor concentrations are 
shown in the Tables I, II, III, IV, V, VI and VII. Pep-
tide nitroanilides with appropriate sequence were used 
as substrates for various serine proteases. All peptide 
4-nitroanilide hydrolysis was measured at 410 nm 
(€410=8800M-lcm-l; Erlanger et al., Arch. Biochem. 
Biophys. 9S, pp 271-278 (1961)). First order inactiva-
tion rate constant (kobs) were obtained from plots of In 
(v1/v0) vs time, and the correlation coefficients were 
greater than 0.98. 
Table I shows the inactivation rate constants of por-
cine pancreatic elastase (PPE), human leukocyte elas-
tase (HLE) inhibited by substituted isocoumarins. The 
inactivation by these inhibitors was less efficient toward 
PPE than HLE. The structures with R group of o-
methoxyphthalylamino or phenylcarbamoylamino, Y 
group of Cl, and Z group of methoxy are best inhibitors 
for PPE. The structures with R group of Tosphenyl-
glycylamino or m-methoxycarbonylaminoben-
zoylamino, Y group of Cl, and Z-group of methoxy are 
best at inhibiting HLE. 
Table II shows the inhibition of PPE by substituted 
isocoumarins, the structure with R group of phenylthi-
ocarbamylamino, Y group of Cl, and Z-group of ethoxy 
is the best inhibitor of PPE. Table III shows the inhibi-
tion of PPE, HLE, chymotrypsin and cathepsin G by 
substituted isocoumarins. It is unexpected that all the 
compounds with Y group of Cl and Z group of propoxy 
are very potent inhibitors ofHLE. The structure with R 
group of phenylcarbamoylamino, or dihydrocin-
namoylamino, Y group of Cl, and Z group of propoxy 
are the best inhibitors of HLE. However they are poor 
inhibitors of cathepsin G. The structure with R group of 
ethoxycarbonylamino, Y group of Cl and Z group of 
propoxy is a good inhibitor for chymotrypsin. 
Table IV shows the inhibition of PPE, HLE, chymo-
trypsin and cathepsin G by biotin isocoumarin deriva-
tives. The compound with R group of 6-
biotinylaminocaproylamino, Y group of Cl and Z group 
of phenylethoxy is a good inhibitor for chymotrysin. 
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The structure with R group of 6cbiotinylaminoca-
proylamino, Y group of Cl and Z group of propoxy or 
ethoxy are the best inhibitors for HLE. 
hibitors described above can be used by any of these 
routes. 
For treatment of inflammation, the compounds of 
Formula (I) may be administered orally, topically or 
parenterally. The term parenteral as used includes sub-
cutaneous injection, intravenous, intramuscular, intra-
sternal injection or infusion techniques. The dosage 
depends primarily on the specific formulation and on 
the object of the therapy or prophylaxis. The amount of 
the individual doses as well as the administration is best 
determined by individually assessing the particular case. 
The pharmaceutical compositions containing the ac-
tive ingredient may be in a form suitable for oral use, for 
Table V shows the inhibition of rat granule chymase 
and tryptase by biotin isocoumarin derivatives. The 5 
structure with a R group of 6-biotinylaminoca-
proylamino, Y group of Cl and Z group of phenyle-
thoxy inactivated chymase instantly with 50% inhibi-
tion, and also inhibited tryptase very slowly. Table VI 
shows the reactivation of inhibited chymotrypsin and 10 
rat granule chymase by biotin isocoumarins in buffer 
and in the presence ofhydroxylamine. Inhibited chymo-
trypsin regained 40-85% of activity and inhibited rat 
granule chymase regained 30-100% of activity in the 
presence of hydroxylamine. 
Table VII shows the inhibition of PPE, HLE, chy-
motrypsin and cathepsin G by isocoumarins substituted 
with bromoalkoxy groups. The structure with R group 
ofR-methylbenzylcarbamylamino, Y group of Cl and Z 
group ofbromoethoxy is the best inhibitor for PPE. It is 20 
unexpected that all the compounds with Y group of Cl, 
Z-group of bromoethoxy are potent inhibitors of HLE, 
especially the structure with R group of phenylcar-
bamoylamino is the most potent inhibitor of HLE. The 
structures with R group ofN02, Y group of Cl, Z group 25 
of 2-bromoisopropoxy and R group of phenylacetyl, Y 
group of Cl, Z-group of bromopropoxy are the best at 
inhibiting chymotrypsin. 
15 example as tablets, troches, lozenges, aqueous or oily 
suspensions, dispersible powders or granules, emulsions, 
hard or soft capsules or syrups or elixirs. Dosage levels 
of the order to 0.2 mg to 140 mg per kilogram of body 
Table VIII shows the half-life for the deacylation of 
inactivated elastase by substituted isocoumarins. Only 30 
the enzyme inactivated by compound with R group of 
phenylcarbamyl, Y group of Cl, and Z group of me-
thoxy is stable with the half-life more than 48 hrs. 
Pulmonary emphysema is a disease characterized by 
progressive loss of lung elasticity due to the destruction 35 
of lung elastin and alveoli. The destructive changes of 
lung parentchyma associated with pulmonary emphy-
sema are caused by uncontrolled proteolysis in lung 
tissues (Janoff, Chest 83 pp 54-58 (1983)). A number of 
proteases has been shown to induce emphysema in ani- 40 
mals (Marco et al., Am. Rev. Respir. Dis. 104, pp 
595-598 (1971); Kaplan, J. Lab. Clin. Med. 82, pp 
349-356 (1973)), particularly human leukocyte elastase 
(Janoff, ibid 115, pp 461-478 (1977)). Leukocyte elas-
tase and other mediators of inflammation also appear to 45 
play a role in diseases such as mucocutaneous lymph 
node syndrome (Reiger et al., Eur. J. Pediatr. 140, pp 
92-97 (1983) and adult respiratory distress syndrome 
(Stockley, Clinical Science 64, pp 119-126 (1983); Lee 
et al., N. Eng. J. Med. 304, pp 192-196 (1981); Rinaldo, 50 
ibid 301, 900-909 (1982)). 
It is known that in vitro activity of elastase inhibitors 
correlates with in vivo activity in animal models of 
emphysema and inflammation (Otterness et al., editor, 
Advances in Inflammation Research, Vol. 11, Raven 55 
Press 1986, and this article is incorporated herein by 
reference). Prophylactic administration of an inhibitor 
of elastase significantly diminishes the extent of elastase-
induced emphysema (Kleinerman et al., Am. Rev. 
Resir. Dis. 121, pp 381-387 (1980); Lucey et al., Eur. 60 
Respir. J. 2, pp 421-427 (1989)). Thus the novel inhibi-
tors described here should be useful for the treatment of 
emphysema and inflammation. Elastase inhibitors have 
been used orally, by injection or by instillation in the 
lungs in animal studies (Powers, Am. Rev. Respir. Dis., 65 
127, s54-s58 (1983); Powers and Bengali, Am. Rev. 
Respir. Dis. 134, pp 1097-1100 (1986) and these two 
articles are incorporated herein by reference). The in-
weight per day are useful in the treatment of above-
indicated conditions (10 mg to 7 gms per patient per 
day). The amount of active ingredient that may be com-· 
bined with carrier materials to produce a single dosage 
form will vary depending upon the host treated and the 
particular mode of administration. 
For injection, the therapeutic amount of the com-
pounds of Formula (I) or their pharmaceutically accept-
able salts will normally be in the dosage range from 0.2 
to 140 mg/kg of body weight. Administration is made 
by intravenous, intramuscular or subscutaneous injec-
tion. Accordingly, pharmaceutical compositions for 
parenteral administration will contain in a single dosage 
form about 10 mg to 7 gms of compounds of Formula 
(I) per dose. In addition to the active ingredient, these 
pharmaceutical compositions will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in 
the range from 3.5 to 7 and also sodium chloride, manni-
tol or sorbitol for adjusting the isotonic pressure. 
A composition for topical application can be formu-
lated as an aqueous solution, lotion, jelly or an oily 
solution or suspention. A composition in the form of an 
aqueous solution is obtained by dissolving the com-
pounds of Formula (I) in aqueous buffer solution of pH 
4 to 6.5 and if desired, adding a polymeric binder. An 
oily formulation for topical application is obtained by 
suspending the compounds of Formula (I) in an oil, 
optionally with the addition of a swelling agent such as 
aluminium stearate and/or a surfactant. 
To use the above inhibitors in vitro, they are dis-
solved in an organic solvent such as dimethylsulfoxide 
or ethanol, and are added to an aqueous solution con-
taining serine proteases. The final concentration of the 
organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine 
protease inhibitors of this invention would be useful in a 
variety of experimental procedures where proteolysis is 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher 
sensitivity. The use of these inhibitors in plasma frac-
tionation procedures would result in higher yields of 
valuable plasma proteins and would make purification 
of the proteins easier. The inhibitors disclosed here 
could be used in cloning experiments utilizing bacterial 
cultures, yeast and purified cloned product in higher 
yield. 
The following examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
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EXAMPLE 1 
Preparation of 
7-heptafluorobutyroylamino-4-chloro-3-methox-
MS m/e 353 (M+). Anal. Cale. for C16H16ClN06: C, 
54.30; H, 4.56; N, 3.96; Cl, 10.03. Found: C, 54.39; H, 
4.58; N, 3.39; Cl, 10.13. 
7 -(methoxysuccinyl)amino-4-chloro-3-ethox-
yisocoumarin 5 yisocoumarin and 7-(methoxysuccinyl)amino-4-chloro-
3-(2-phenylethoxy)isocoumarin was prepared by the 
same procedure. 
7-Amino-4-chloro-3-methoxyisocoumarin (1 eq.) and 
heptafluorobutyryl chloride (1.5 eq.) were dissolved in 
T!fF and.then Et3N (1.5 eq.) was added dropwise to the 
stirred mIXture over a period of 4 h. After addition of 
Et3N was completed, the reaction mixture was stirred 10 
for 20 hat r.t., then the solvent was removed in vacuo 
and the residue dissolved in ethyl acetate. This solution 
was washed with water, 10% citric acid, 4% NaHC03 
and finally again with water, dried over MgS04 and 
evaporated. The residue was crystallized from THF- 15 
hexane to give yellow solid; yield 62%; mp 189°-190° 
C.; MS, m/e 421 (M+). Anal. Cale. for C1~7F1ClN04: 
EXAMPLE4 
Preparation of 
7-[(N-tosyl-a-phenylglycyl)amino]-4-chloro-3-methox-
yisocoumarin 
N-Tosyl phenylglycine (1.8 mmole) was dissolved in 
2 ml of SOC]i and stirred at reflux temperature for 40 
~· The reaction mixture was concentrated to dryness 
m vacuo and the residue triturated with EtOAc/Hex-
ane (3:1) to yield the acid chloride (94%) which is used 
in the next step without further purification. Tos-C, 39.84; H, 1.66; N, 3.32. Found: C, 40.24· H, 1.70· N 3.33. , , , 
20 phenylglycine acid chloride (155 mg) and 7-amino-4-
chloro-3-methoxyisocoumarin (72 mg) were dissolved 
in a mixture of methylene chloride (1 ml) and THF (1 
ml). A solution of triethylamine (0.06 ml in 2 ml of 
CH2Cli) was added dropwise and the reaction mixture 
7-(3-fluorobenzoyl)amino-4-chloro-3-propox-
yisocoumarin, 7-( 4-methoxybenzoyl)amino-4-chloro-3-
propoxyisocoumarin, 7-heptafluorobutyroylamino-4-
chloro-3-ethoxyisocoumarin, 7-hepta-
fluorobutyroylamino-4-chloro-3-(2-bromoethox-
y)isocoumarin, 7-heptafluorobutyroylamino-4-chloro- 25 
3-(2~phenylethoxy)isocoumarin, 7-(3-fluorobenzoyl-
)ammo-4-chloro-3-(2-bromoethoxy )isocoumarin, 7-(3-
nitrobenzoyl)amino-4-chloro-3-(2-bromoethox-
y)isocoumarin, 7-(a-toluenesulfonyl)amino-4-chloro-3-
(2-bromoethoxy)isocoumarin can be prepared by the 30 
same procedure. 
EXAMPLE2 
Preparation of 
7-[ (3-pheny lg! utary l)amino )-4-chloro-3-methox-
yisocoumarin 
One gram of 7-amino-4-chloro-3-methoxyisocouma-
35 
rin dissolved in 15 ml of pyridine was treated with 4 
equivalents of 3-phenylglutaric anhydride. After 5 hrs, 40 3 ml of water were added to the reaction mixture. Par-
tial evaporation of the solvents left a semisolid residue, 
which was diluted with a mixture of acetone and water 
(3:1_), and filtered. The crude crystals were then recrys-
tallized from acetone/water to give yellow crystals 
yield 62%.; mp 105°-106° C.; MS (FAB+) m/e 416 45 
(M++l). Anal. Cale. for C21H1sCIN06.l.2H20: C, 
57.66; H, 4.42; Cl, 3.20. Found: C, 57.60; H, 4.77; N, 
3.17. . 
7-( o-phthalyl)amino-4-chloro-3-ethoxyisocoumarin 
and 7-(o-phthalyl)amino-4-chloro-3-(2-phenylethox- 50 
y)isocoumarin can be prepared by the same procedure. 
EXAMPLE3 
was stirred at room temperature for 2 h. The solvent 
was removed in vacuo and the residue was triturated 
with ethyl acetate (1.5 ml). The resulting yellow solid 
was recrystallized from THF /H20 to yield 108 mg 
(66%); mp 150'-151' C. (dee.); MS, m/e 512 (M+). 
Anal. Cale. for C2sH21ClN206S: C, 58.53; H, 4.13; N, 
5.46. Found: C, 58.43; H, 4.15; N, 5.40. 
EXAMPLES 
Preparation of 
7-(N-phenylearbamoylamino)-4-chloro-3-methox-
yisocoumarin 
This compound was prepared by reaction of 110 mg 
(0.5 mmol) of 7-amino-4-chloro-3-methoxyisocoumarin 
with 60 mg (0.5 mmol) of phenyl isocyanate at room 
temperature in CH2Clz for 24 h. After standard work-
up, this isocoumarin was obtained as yellow crystals· 
mp 203'-204' C.; MS, m/e 344 (M+). Anal. Cale. fo; 
C17H13ClN204: C, 59.23; H, 3.08; N, 8.13; Cl, 10.28. 
Found: C, 59.28; H, 3.82; N, 8.11; Cl, 10.35. 
7-benzylamino-4-chloro-3-ethoxyisocoumarin and 
7-benzylamino-4-chloro-3-(2-phenylethoxy)isocouma-
rin can be prepared by the same procedure. 
EXAMPLE6 
Preparation of 
4-chloro-7-phenylthiocarbamoylamino-3-ethox-
yisocoumarin 
This compound was preparation by reaction of 7-
Preparation of 55 amino-4-chloro-3-ethoxyisocoumarin with phenyl iso-7-[(methoxyglutaryl)amino ]-4-chloro-3-methox- thiocyanate at r.t. in THF for 24 hrs. The product was 
yisocoumarin obtained as yellow solid: yield 55%, m.p. 176'-177' C. 
7-Glutarylamino-4-chloro-3-methoxyisocoumarin (dee.); TLC, Rp0.76 (CH3Cl:Me0H=9:1), MS 
was prepared by the same procedure described in exam- mle=374 (M+). Anal. Calcd. for C1sH1sN203CIS: C, 
pie 2, mp 194° C. (dee.); MS m/e 339 (M+). Anal. Cale. 60 57.62; H, 4.00. Found: C, 57.77; H, 4.04. 
for C1sH14ClN06.1.2 HzO: C, 57.66; H, 4.42; N, 3.20. EXAMPLE 7 
Found: C, 57.60; H, 4.77; N, 3.17. An etheral solution 
containing 2.5 mmoles of diazomethane was added to a 
solution of 0.6 mmoles of 7-glutarylamino-4-chloro-3-
methoxyisocoumarin in a mixture of DMF and ethyl 65 
acetate. After 30 min, the reaction mixture was evapo-
rated to dryness and the crude ester crystallized from 
acetone, giving a yellow solid, mp 147'-151' C. (dee.); 
Preparation of 
7-dihydrocinnamoylamino-4-chloro-3-propylox-
yisocoumarin 
This compound was synthesized by reaction of equi-
molar of 7-amino-4-chloro-3-propoxyisocoumarin, 
dihydrocinnamic acid chloride and triethylamine in dry 
15 
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THF. The reaction mixture was stirred overnight, and 
the solution was washed with water, 4% NaHC03, 
water and dried over MgS04. After filtration and evap-
oration, a yellow residue was crystallized from THF-
pentane, yield 81%; mp 182°-184° C.; TLC, Rp0.74 5 
(CH3Cl:Me0H=9:1); MS, m/e 385 (M+). Anal. Cale 
for C21H2004NCI.0.5H20: C, 63.81; H, 5.32. Found: C, 
63.47; H, 5.30. 
7-phenoxycarbonylamino-4-chloro-3-ethox-
yisocoumarin and 7-phenoxycarbonylamino-4-chloro- 10 
3-(2-phenylethoxy)isocoumarin can be prepared by the 
same procedure. 
EXAMPLE 8 
Preparation of 
7-(Boc-valyl)amino-4-chloro-3-propyloxyisocoumarin 
15 
This compound was synthesized by reaction of an 
equimolar amount of 7-amino-4-chloro-3-propox-
yisocoumarin and Boe-Val anhydride in THF. The 
reaction mixture was stirred overnight. The work-up as 20 
described above gives a yellow solid which was recrys-
tallized from THF-pentane, yield 48%: mp 171°-173° 
C.; TLC, Rp0.8 (CH3CJ:Me0H=9:1); MS, m/e 452 
(M+). Anal. Cale. for C22H2906N2CI: C, 58.35; H, 6.41; 
N, 6.19; Cl, 7.83. Found: C, 58.40; H, 6.47; N, 6.20; CJ, 25 
7.79. 
7-(Boc-phenylalanyl)amino-4-chloro-3-propylox-
yisocoumarin, 7-(benzoylalanylalanyl)amino-4-chloro-
3-propyloxyisocoumarin, 7-(Boc-valyl)amino-4-chloro-
3-ethoxyisocoumarin, 7-(Boc-alanyl)amino-4-chloro-3- 30 
ethoxyisocoumarin and 7-(Boc-alanyl)amino-4-chloro-
3-(2-phenylethoxy)isocoumarin can be prepared by the 
same procedure. 
EXAMPLE 9 
Preparation of 
7-ethylearbamoylamino-4-chloro-3-propylox-
yisocoumarin 
35 
This compound was synthesized by the reaction of an 
equimolar amount of 7-amino-4-chloro-3-propox- 40 
yisocoumarin and ethyl isocyanate in small amount of 
dry THF. The reaction mixture was stirred at r.t. for a 
few days. During this time the yellow crystals .slowly 
crystallized out. After filtration, the compounds were 
recrystallized once more from THF-pentane, yield 45 
45%; mp 189°-191° C.; TLC, Rp0.43 
(CH3CJ:Me0H=9:1); MS, m/e 324 (M+). Anal. Cale. 
for C1sH1104N2CI: C, 55.42; H, 5.23. Found: C, 55.31; 
(0.32 g, 1 mmole) was mixed with phenylisocyanate 
(0.12 g, 1 mmole) in 5 ml of THF and the reaction mix-
ture was stirred at r.t. overnight. The product 7-
(phenylearbamoylamino )-4-chloro-3-(2-bromoethox-
y )isocoumarin precipitated out, yield 40%, mp. 
215°-217° C.; MS, m/e 437.9 (M+). Anal. Cale. for 
C1sH14N204CIBr: C, 49.40; H, 3.22; N, 6.40; CJ, 8.10. 
Found: C, 49.48; H, 3.25; N, 6.34; Cl, 8.12. 
7-(4-Fluorobenzyl)thiocarbamoylamino-4-chloro-3-
(2-bromoethoxy)isocoumarin, and 7-(2,4-dimethylben-
zyl)thiocarbamoylamino-4-chloro-3-(2-bromoethox-
y)isocoumarin and 7-(4-fluorobenzyl)thiocar-
bamoylamino-4-chloro-3-(2-phenylethoxy)isocoumarin 
can be prepared by the same procedure. 
EXAMPLE 12 
Preparation of 
7-(acetylamino )-4-chloro-3-(3-bromopropox-
y)isocoumarin 
7-Amino-3-(3-bromopropoxy)-4-chloroisocoumarin 
was synthesized similarly as described in Example 10. 
This compound (0.33 g, 1 mmole) was heated with 0.15 
g of acetic anhydride (1.5 mmole) in 20 ml of dry THF. 
After a few minutes, yellow solid was precipitated out. 
After 3 hrs, the solution was concentrated to 5 ml, and 
the solid was filtered to give 0.37 g of 7-(acetylamino)-
4-chloro-3-(3-bromopropoxy)isocoumarin, mp. 
170°-172° C.; MS, m/e 375 (M+). Anal. Cale. for 
C14ff13N04ClBr: C, 44.89; H, 3.50. Found: C, 44.95; H, 
3.54. 
EXAMPLE 13 
Preparation of 
7-(R-a-methylbenzylearbamoylamino )-4-chloro-3-(2-
bromoethoxy )isocoumarin 
This compound was synthesized by the reaction of 
7-amino-4-chloro-3-(2-bromoethoxy )isocoumarin with 
R-a-methylbenzyl isocyanate as described above, mp. 
183°-185° C.; MS m/e 464 (M+). Anal. Cale. for 
C20H1sN204CIBr: C, 51.58; H, 3.90. Found: C,51.66; H, 
3.90. 
EXAMPLE 14 
Preparation of 
7-(Boc-D-phenylalanylamino)-4-chloro-3-(2-bromoe-
thoxy )isocoumarin 
Boc-D-Phe (0.33 g, 1.2 mmole) reacted with 1,3-dicy-H, 5.28. 
EXAMPLE 10 
Preparation of 
7-amino-4-chloro-3-(2-bromoethoxy)isocoumarin 
SO clohexylcarbodiimide (0.13 g, 0.6 mmole) in 10 ml THF 
at o· c. for 1 hr to form the symmetric anhydride, and 
then 7-arnino-4-chloro-3-(2-bromoethoxy)isocoumarin 
(0.2 g, 0.6 mmole) was added. The reaction was stirred 
at r.t. overnight and 7-(Boc-D-phenylarnino)-4-chloro-
This compound was prepared by cyclization of 1 SS 3-(2-bromoethoxy)isocoumarin was precipitated out 
equivalent of bromoethyl nitrohomophthalate with 2.5 (0.29 g, 71 %), mp. 180° -182° C.; TLC, Rp0.95 
equivalent of PCls, followed by catalytic reduction of (CH3Cl:Me0H=9:1); MS m/e=566 (M+). Anal. Cale. 
the nitro group. The product was yellow solid, mp for c25H26N2o6C1Br: C, 53.07; H, 4.63; N, 4.95; Cl 6.27. 
134°-137° C.; MS, m/e 317 (M+). Anal. Cale. for Found: C,53.25; H, 4.66; N, 4.87; Cl, 6.24. 
CnH9N03ClBr: C, 41.44; H, 2.83, N, 4.40. Found: C, 60 7-(Benzoyl-L-alanylamino)-4-chloro-3-(2-bromoe-
42.ll; H, 2.87; N, 4.46. thoxy)isocoumarin and 7-(benzoyl-L-alanylarnino)-4-
EXAMPLE 11 chloro-3-(2-phenylethoxy)isocoumarin can be prepared 
Preparation of 
7-(phenylearbamoylamino)-4-chloro-3-(2-bromoethox-
y )isocoumarin 
7-Amino-3-(2-bromoethoxy)-4-chloroisocoumarin 
was synthesized as described above. This compound 
by the same procedure. 
7-(D-Phenylalanylamino)-4-chloro-3-(2-bromoethox-
65 y)isocoumarin and 7-(alanylalanylamino)-4-chloro-3-(2-
bromoethoxy)isocoumarin can be prepared by deblock-
ing the Boe group of 7-(Boc-D-phenylalanylamino)-4-
chloro-3-(2-bromoethoxy)isocoumarin and 7-(Boc-D-
17 
5,089,633 
18 
alanylalanylamino )-4-chloro-3-(2-bromoethox-
y )isocoumarin with trifluoroacetic acid. 
EXAMPLE 15 
TLC, Rp0.25 (CH2Cli:Me0H=15:1). Anal. Cale. for 
C21H28N305ClS.0.25 H20: C, 59.39; H, 5.22, N, 7. 70. 
Found: C, 59.08; H, 5.37; N, 7.94. 
7-(Biotinylamino )-4-chloro-3-(pentafluoropropox-
Preparation of 5 y)isocoumarin can be prepared by the same procedure. 
7-dansy lamino-4-chloro-3-(2-bromoethoxy )isocoumarin 
EXAMPLE 17 
Dansyl chloride (0.17 g, 0.63 mmole) was mixed with 
7-amino-4-chloro-3-(2-bromoethoxy)isocoumarin (0.2 
g, 0.63 mmole) in 5 ml of THF, and Et3N (0.065 g) was 
then added. The reaction mixture was stirred at r. t. for 10 
a few days, and a yellow solid precipitated out. The 
final product was crystallized from THF /hexane, yield 
41%, mp 114°-117° C.; MS, m/e 552 (M++l). Anal. 
Cale. for C23H21N205ClBrS.1.5H20: C, 47.63; H, 4.14. 
Preparation of 
7-[(6-biotinylamino)caproyl]amino-4-chloro-3-(2-
phenylethoxy)isocoumarin 
Found: C, 47.41; H, 4.27. 15 
6-(Biotinylamino)caproic acid was prepared from 
N-hydroxysuccinimido biotinate (Jasiewicz et al., Exp. 
Cell Res. 100, pp 213-217 (1976)) and methyl 6-
aminocaproic acid hydrochloride by a previously de-
scribed method (Hofmann et al., Biochemistry 23, pp 
2547-2553 (1984)). 6-(Biotinylamino)caproic acid chlo-7-(p-Toluenesulfonyl)amino-4-chloro-3-(2-bromoe-
thoxy )isocoumarin and 7-(p-toluenesulfonyl)amino-4-
chloro-3-(2-phenylethoxy)isocoumarin can be prepared 
by the same procedure. 
ride was synthesized and reacted with 7-amino-4-
chloro-3-(2-phenylethoxy)isocoumarin as described 
above. The product was purified by column chroma-
20 tography, mp 163°-167° C. Anal. Cale. for 
C33H39N406ClS.H20: C, 58.72; H, 6.22; N, 8.96; Cl, 
5.59. Found: C, 58.87; H, 6.14; N, 8.32; Cl, 5.27. 
EXAMPLE 16 
Preparation of 
TABLE I 
Inhibition Constants for Inactivation of Elastases by 7-substituted-'k:hloro-3-
methox:ijsocoumarins•. 
HLE PPE 
Compounds [I] kobsl[I] [I] kobsl[I] 
7-Substituent (JLM) (M-ls-1) (µM) (M-ls-1) 
NCO 1.8 9,200 8.3 650 
EtOCONH 2.3 47,000 8.3 2,000 
PhOCONH 1.8 13,000 8.8 850 
PhCH20CONH 1.6 71,000 136.0 260 
H2NCONH 8.2 2,100 
CH3NHCONH 3.3 9,460 13 1,300 
EtNHCONH 6.3 1,700 
i-PrNHCONH 3.0 9,000 12 2,300 
t-BuNHCONH 6.6 20,000 13 3,200 
PhNHCONH 2.0 49,000 8.3 7,300 
PhCH2(PhCH2CH2)NCONH 2.2 12,000 490.0 17 
C3F7CONH 2.7 47,000 17.0 1,100 
Fmoc-NH 2.5 10,000 600.0 20 
Tos-Phenylglycyl-NH 1.6 84,000 8.3 1,500 
o-HOOCC(Jl4CONH 1.8 52,000 17.0 2,700 
o-CH300CC(Jl4CONH 8.3 7,100 
CH300CCH2CH2CONH 2.3 43,000 17.0 2,200 
CH300CCH2CH2CH2CONH 2.3 54,000 8.3 2,800 
HOOCCH2CH(Ph)CH2CONH 1.6 66,000 8.3 3,100 
m-CH300CNHC(Jl4CONH 1.4 100,000 17.0 2,500 
"Inhibition constants were in 0.1 M Hepes, O.S M NaCl, pH 7.S buffer, 8-9% MeiSO and at 2s• C. 
7-(biotinylamino )-4-chloro-3-(2-phenylethox-
y )isocoumarin 
Biotin acid chloride was prepared by incubating 0.4 g 
of biotin in 6 ml of thionyl chloride at 25° -35° C. for 1 
50 
hr, and excess thionyl chloride was removed under 
vacuum. The acid chloride was used for the next step 
without further purification. Biotin acid chloride and 55 
7-amino-4-chloro-3-(2-phenylethoxy)isocoumarin (0.26 
TABLE II 
Inhibition Rates of Inactivation of Porcine 
Pancreatic Elastase by 7-Substituted-4-
chloro-3-cthoxyisocoumarin0. 
Compounds [I] 
7-Substituent (JLM) 
EtO-CO-NH 
Et-NH-CS-NH 
Ph-NH-CS-NH 
9.6 
20-50 
9-31 
3,500 
4,200 
12,000 
g) was dissolved in small amount of DMF, and then 
Et3N (0.08 g) were added. The reaction mixture was 
stirred at r.t. overnight. The product was purified by 
column chromatography, yield 0.1 g, mp 182°-185° C.; 
"Inhibition rates were measured in 0.1 M Hepes, O.S M NaCl, 8.3% MeiSO, pH 7.S 
and at 2s· C. 
TABLE III 
Inhibition Rates of Inactivation of Serine Proteases by Derivatives 
of 7-Subsitituted-'k:hloro-3-propylox:ijsocoumarins0. 
Compounds k,,bsl'[l] (M-ls-1) 
7-Substituted PPEb HLF Chymotrypsind Cathepsin G' 
PhCH2CH2CONH 
CH3CH20CONH 
CH3CH2NHCONH 
220 
1,600 
>250,000 
> 181,000 12,000 
>276,000 5,200 
20 
138 
166 
5,089,633 
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TABLE III-continued 
Inhibition Rates of Inactivation of Serine Proteases by Derivatives 
of 7-Subsitituted-4-chloro-3-propyloxyisocoumarins0 . 
Compounds 
7-Substituted 
PhNHCONH 
PHNHCSNH 
PhCH2NHCSNH 
3-N02-C614CONH 
CH3SCH2CONH 
Boe-Val-NH 
pp£b 
80 
520 
HLE< Chymotrypsind 
143,000 120 
> 166,000 6,100 
>131,000 
>210,000 
>152,000 
64,000 
Cathepsin G' 
NI 
4 
28 
17 
"Inhibition rates were measured in 0.1 M Hepes, 0.5 M NaCl, 2.5% Me2SO, pH 7.5 and at 25' C. 
hinhibitor concentrations were ~S6 µM. 
'"Inhibitor concentrations were 0.7-1.9 µM. 
dlnhibitor concentrations were 3.4-70 µM. 
'Inhibitor concentrations were 8.7-87 µM. 
TABLE IV 
Inhibition of Serine Proteases by Biotin-Isocoumarin Derivatives". 
k,,b,/UJ (M-1s-1l 
Compounds Chymotrypsinb Cat. Ge HLEd PPE' 
7-biotinylamino-4-chloro- 330 NI 740 NI 
3-(2-phenylethoxy)isocoumarin 165 
7-biotinylamino-4-chloro- 65 6.7 19,900 470 
3-propoxyisocoumarin 
7-(6-biotinylaminocaproyl)amino-4-chloro- 1,080 13% 670 NV 
3-(2-phenylethoxy)isocoumarin 190 
7-(6-biotinylaminocaproyl)amino- 260 3.3 76,700 350 
4-chloro-3-propoxyisocoumarin 
7-(6-biotinylaminocaproyl)amino- 260 59 96,000 520 
4-chloro-3-ethoxyisocoumarin 
"Inhibition was measured in 0.1MHepes,0.5 M NaCl, pH 7.5 buffer, 5-10% Me2SO and at 25' C. Suc-Val-Pro-
Phe-NA (0.48 mM) was used as the substrate for chymotrypsin and cat G. MeO-Suc-Ala-Ala-Pro-Val-NA 
(0.24-0.47 mM) and Sue-Ala-Ala-Ala-NA (0.29-0.48 mM) were used as the substrate for HLE and PPE 
respectively. 
11.nhibitor concentrations were 20-400 µM. 
'Inhibitor concentrations were 75~ µM. 
dJnhibitor concentrations were 2.0-78 µM. 
f'J.nhibitor concentrations were 38-78 µM. 
INo inhibition. 
TABLE V 
Inhibition of Rat granule Serine Proteases by Biotin-Isocoumarin Derivatives". 
[I] Rat Granule Chymase Rat Granule Tryptase 
Compounds (mM) % of inhibitionb kobsl[I] (M-ls-1) 
7-(6-Biotinylaminocaproyl)amino-4-chloro-
3-(2-phenylethoxy)isocoumarin 
7-Biotiny lamino-4-chloro-
3-(2-phenylethoxy )isocoumarin 
O.D78 
0.2 
30-50 6-12 
10-20 2-3 
"Inhibition was measured at 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer, 10% Me2SO and 25' C. Suc-Phe-Leu-Phe-SBzl (0.14 
mM) and Z-Gly-Arg-SBzl (0.06 mM) were used to measure chymase and tryptase activity respectively. 
61.nhibition was not time dependent. 
TABLE VI 
Reactiviation of Inhibited Chymotrypsin and Rat Granule Chymase by Biotin-Isocoumarin 
Derivatives in Buffer and in the Presence of NH20Ha. 
Inhibitor 
7-(6-Biotinylaminocaproyl)amino-4-chloro-
3-(2-phenylethoxy)isocoumarin 
7-Biotinylamino-4-chloro-
3-(2-phenylethoxy)isocoumarin 
[I] 
(µM) 
39 
78 
39 
78 
% of Enzyme Activity Reactivated 
Chymotrypsin Rat granule chymase 
in bufferb +NH20H +NH20H 
6 50 
0 40 30-50 
51 85 
7 79 100 
"Inhibition was performed at 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer, 10% Me2SO and 25' C. Reactivation was carried out 
in the presence of 0.36 M of NH20H, and occurred immediately after the addition of NH20H. 
"Enzyme activity was measured after two days. 
TABLE VII 
Inhibition Rates of Serine Proteases by 7-substituted-4-chloro-3-bromoalkoxyisocoumarins 
and 7-amino-4-chloro-3-alkoxyisocoumarins0 • 
Compounds pp£b HLE< Chymotrypsind Cathepsin G' 
(I) 7-substituted-4-chloro-3-(2-bromoethoxy)isocoumarin 
20 
21 
5,089,633 
22 
TABLE VII-continued 
Inhibition Rates of Serine Proteases by 7-substituted-4-chloro-3-bromoalkoxyisocoumarins 
and 7-amino-4-chloro-3-alkoxyisocoumarins0 . 
Compounds PPE6 HLF Chymotrypsind Cathepsin G' 
7-NH2 
7-N02 
7-(t-Bu-NH-CO-NH) 
7-(isopropyl-NH-CO-NH) 
7-(Ph-NH-CO-NH) 
7-(Ph-CH2-NH-CO-NH) 
7-(R-(4ff5)(CH3)CH-NH-CO-NH) 
7-(S-(C6fl5)(CH3)CH-NH-CO-NH) 
7-(Naphthyl-NH-CO-NH) 
7-((CH3)3C-CH2CO-NH) 
7-(Ph-CH2-CO-NH) 
7-(Boc-D-Phe-NH) 
7-(Boc-L-Phe-NH) 
7-(Boc-Ala-Ala-NH) 
1,000 
6,330 
6,600 
4,470 
36 
3,010 
9,900 
2,660 
76 
3,650 
4,950 
30 
50 
1,670 
200,ooof 1,160 
65,600 98.~ 
646.~ 
1,200.~ 
480.~ 
>440.~ 
>570.~ 
390.~ 
480.~ 
230.~ 
320 
134QH 
12 
890 
18oh 
440 
80 
1,070 
82.~ 
150 
400 
2,15oh 
810h 
7-(PhNHCSNH) 1,250 >480,~ 39,~ 
7-(m-COOH-PhNHCSNH) >240,~ 1,960 
7-(p-COOH-PhNHCSNH) >390,~ 1,720 
(11). 7-substituted-4-chloro-3-(3-bromopropoxy)isocoumarin 
7-NH2 
7-N02 
7-(Ph-NH-CO-NH) 
7-(Ph-CH2-NH-CO-NH) 
7-(CH3-CO-NH) 
7-(Ph-CH2-CO-NH) 
7-(Ph-CH2CH2CO-NH) 
10 4,000 790 
4 
13 
24 
28 
13,75oh 
2,890h 
15,650 
24,400 
32,350 
35,650h 
9,87oh 
180 
440 
3,980 
140.~ 
600 
7-(Boc-D-Phe-NH) 1,480 70 
7-(Boc-L-Phe-NH) 1,320 490 
(Ill). 7-substituted-4-chloro-3-(2-bromoisopropoxy)isocoumarin 
1,060 200.~ 
62 . 24,000 320 
(IV). 7-amino-4-chloro-3-alkoxyisocoumarin 
3-CH3CH2CH20 
3-CH3CH2CH20CH2CH 20 
4.3 390 
0.5 33 
375 
140 
410 
710 
56 
77 
Nii 
23o/d 
77 
21 o/d 
22o/d 
240 
70 
19o/d 
19o/d 
46 
200 
320 
450 
210 
17o/d 
2lo/d 
170 
28o/d 
NI 
NI 
NI 
1,660 
150 
61 
2.6 
°Inhibition rates were measured in 0.1 M Hepes, 0.5 M NaCl. pH 7.5 buffer, 8-9% Me2SO and at 25° C. Substrates 
were Sue-Ala-Ala-Ala-NA (0.48 mM) for PPE; MeO-Suc-Ala-Ala-Pro-Val-NA (0.24 mM) for HLE; Suc-Val-
Pro-Phe-NA (0.48 mM) for chymotrypsin and cathepsin G. 
hinhibitor concentrations were 0.04--2.0 mM. 
"Inhibitor concentrations were 0.07-710 mM. 
dlnhibitor concentrations were 1.7-58 mM. 
~nhibitor concentrations were 35 -710 mM. 
/p,.ogress curve method was used according to Tian & Tsou (1982) Biochemistry 21, 1028-1032. 
BSecond order rate constant was obtained using equimolar concentration of inhibitor and enzyme. 
hsiphasic plot was obtained, and two inhibition rates were shown. 
'NI = No inhibition . 
.ipercentage of inhibition was obtained after 5 min incubation of inhibitor with enzyme. 
50 
0 Rwll I o 
# # OMe 
y 
________ T_A_B_L_E_V_II_I ________ 55 or a pharmaceutically acceptable salt thereof, wherein 
Half-Lives for Deacylation of Elastases Inactivated by 
7-Substituted-4-chloro-3-methoxyisocoumarins0 . 
Compounds t1 (h) 
7-Substituted HLE PPE 
HOOCCH2CH2CONH 
HOOCCH2CH2CH2CONH 
o-HOOCC614CONH 
CH300CCH2CH2CH2CONH 
Ph NH CO NH 
1.5 
1.7 
5.0 
1.0 
>48 
1.3 
1.5 
17 
1.0 
>48 
60 
°Enzyme activity was followed after removal of excess inhibitors by centrifugation 
using Amicon ccntricon·IO microconcentrator. 65 
What is claimed is: 
1. A compound of the formula: 
R is selected from the group consisting of O=C-
N-, S==C=N-, M-NH-, M-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CS-, X-S02-, 
X-0-CO-, X-0-CS-, or D-CO-, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl sub-
stituted with K, 9-fluorenylmethyl, phenyl, phenyl 
substituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, naphthyl, naphthyl 
substituted with J, naphthyl disubstituted with J, 
naphthyl trisubstituted with J, C1-6 alkyl with an 
23 
5,089;633 
24 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, omithine or sarco-
sine. 
attached phenyl group, C1-6 alkyl with two at-
tached phenyl groups, C1-6 alkyl with an attached 
phenyl substituted with J, or C1-6 alkyl with two 
attached phenyl groups substituted with J, 3. The compound of claim 2, wherein AA is a 
5 blocked or unblocked amino acid. wherein D represents C1-6 fluoroalkyl, C1-6 alkyl 
substituted with K, C1-6 fluoroalkyl substituted 
with K, 9-fluorenylmethyl, phenyl, phenyl substi-
tuted with J, phenyl disubstituted with J, phenyl 
trisubstituted with J, naphthyl, naphthyl substi-
tuted with J, naphthyl disubstituted with J, naph- 10 
thy! trisubstituted with J, C1-6 alkyl with an at-
tached phenyl group substituted with J, or C1-6 
alkyl with two attached phenyl groups substituted 
with J, 
wherein J represents halogen, COOH, OH, CN, N02, 15 
NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 al-
kyl-0-CO-NH-, or C1-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 20 
dialkylamine, C1-6 alkyl-0-CO-, or C1-6 al-
kyl-0-CO-NH, Ct-6 alkyl-S-, or 
tosylamino, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
2. A compound of the formula: 
0 
R~~ 
~OMe 
y 
25 
30 
or a pharmaceutically acceptable salt thereof, wherein 35 
R is selected from the group consisting of 
M-AA-NH- and M-AA-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 40 
X-0-CO-, or X-0-CS-, 
wherein X represents Ct-6 alkyl, Ct-6 fluoroalkyl, 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl sub-
stituted with K, 9-fluorenylmethyl, phenyl, phenyl 
substituted with J, phenyl disubstituted with J, 45 
phenyl trisubstituted with J, naphthyl, naphthyl 
substituted with J, naphthyl disubstituted with J, 
naphthyl trisubstituted with J, C1-6 alkyl with an 
attached phenyl group, Ct-6 alkyl with two at-
tached phenyl groups, C1-6 alkyl with an attached 50 
phenyl group substituted with J, or Ct-6 alkyl with 
two attached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, Ct-6 alkyl, C1-6 alkoxy, Ct-6 alkylamine, C1-6 
dialkylamine, Ct-6 alkyl-0-CO-, Ct-6 al- 55 
kyl-0-CO-NH-, or Ct-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, Ct-6 alkylamine, Ct-6 
dialkylamine, Ct-6 alkyl-0-CO-, or Ct-6 al-
kyl-0-CO-NH, Ct-6 alkyl-S-, or 60 
tosylamino, 
Yis selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy, and 
wherein AA represents alanine, valine, leucine, iso-
leucine, methionine, phenylalanine, glycine, serine, 65 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
beta-alanine, norleucine, norvaline, phenylglycine, 
4. A compound of the formula: 
0 
I o Rwll
#. # OEt 
y 
or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting of O=C-
-N-, S=C=N-, M-NH-, M-0-, 
wherein M represents NH2-CS-, NH2-S02-, 
L-NH-CO-, X-NH-CS-, X-N-
H-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein L represents Ct-6 fluoroalkyl, Ct-6 alkyl 
substituted with K, Ct-6 fluoroalkyl substituted 
with K, 9-fluorenylmethyl, phenyl substituted with 
J, phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstitu-
ted with J, Ct-6 alkyl with an attached phenyl 
group, C1-6alkyl with two attached phenyl groups, 
C1-6 alkyl with an attached phenyl group substi-
tuted with J, or Ct-6 alkyl with two attached 
phenyl groups substituted with J, 
wherein X represents Ct-6 alkyl, Ct-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl sub-
stituted with K, 9-fluorenylmethyl, phenyl, phenyl 
substituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, naphthyl, naphthyl 
substituted with J, naphthyl disubstituted with J, 
naphthyl trisubstituted with J, C1-6 alkyl with an 
attached phenyl group, C1-6 alkyl with two at-
tached phenyl groups, Ct-6 alkyl with an attached 
phenyl group substituted with J, or Ct-6alkyl with 
two attached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamine, Ct-6 
dialkylamine, Ct-6 alkyl-0-CO-, Ct-6 al-
kyl-0-CO-NH-, or Ct-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Ct-6 alkoxy, Ct-6 alkylamine, C1-6 
dialkylamine, Ct-6 alkyl-0-CO-, or Ct-6 al-
kyl-0-CO-NH, C1-6 alkyl-S-, or 
tosylamino, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
5. A compound of the formula: 
0 
R~~ 
~OEt 
y 
or a pharmaceutically acceptable salt thereof, wherein 
25 
5,089,633 
26 
R is selected from the group consisting of 
M-AA-NH- and M-AA-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 5 
X-0-CO-, or X-0-CS-, 
wherein X represents Ct-6 alkyl, Ct-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl sub-
stituted with K, 9-fluorenylmethyl, phenyl, phenyl 
substituted with J, phenyl disubstituted with J, 10 
phenyl trisubstituted with J, naphthyl, naphthyl 
substituted with J, naphthyl disubstituted with J, 
naphthyl trisubstituted with J, Ct-6 alkyl with an 
attached phenyl group, Ct-6 alkyl with two at-
tached phenyl groups, Ct-6 alkyl with an attached 15 
phenyl group substituted with J, or C1-6alkyl with 
two attached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, Ct-6 
dialkylamine, C1-6 alkyl-0-CO-, Ct-6 al- 20 
kyl-0-CO-NH-, or C1-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Ct-6 alkoxy, Ct-6 alkylamine, Ct-6 
dialkylamine, Ct-6 alkyl-0-CO-, or Ct-6 al-
kyl-0-CO-NH, Ct-6 alkyl-S-, or 25 
tosylamino, 
Yis selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy, and 
wherein AA represents alanine, valine, leucine, iso-
leucine, methionine, phenylalanine, glycine, serine, 30 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
beta-alanine, norleucine, norvaline, phenylglycine, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, omithine or sarco- 35 
sine. 
6. The compound of claim 5, wherein AA is a 
blocked or unblocked amino acid. 
7. A compound of the formula: 
0 
R~~ 
~OPr 
y 
or a pharmaceutically acceptable-salt thereof, wherein 
40 
45 
R is selected from the. group consisting of O=C- 50 
N-, S=C=N-, M-NH-, M-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, X-0-CS-, 55 
wherein X represents C1-6 alkyl, Ct-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl sub-
stituted with K, 9-fluorenylmethyl, phenyl, phenyl 
substituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, naphthyl, naphthyl 60 
substituted with J, naphthyl disubstituted with J, 
naphthyl trisubstituted with J, Ct-6 alkyl with an 
attached phenyl group, Ct-6 alkyl with two at-
tached phenyl groups, C1-6 alkyl with an attached 
phenyl group substituted with J, or C1-6alkyl with 65 
two attached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, Ct-6 alkyl, C1-6 alkoxy, Ct-6 alkylamine, Ct-6 
dialkylamine, Ct-6 alkyl-0-CO-, Ct-6 al-
kyl-0-CO-NH-, or C1-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Ct-6 alkoxy, Ct-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, or C1-6 al-
kyl-0-CO-NH, C1-6 alkyl-S-, or 
tosylamino, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
8. A compound of the formula: 
0 
I o Rwll
,# ,# OPr 
y 
or a pharmaceutically acceptable salt thereof, wherein 
R is selected from the group consisting of 
M-AA-NH- and M-AA-0-, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, X-0-CS-, 
wherein X represents C1-6 alkyl, Ct-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl sub-
stituted with K, 9-fluorenylmethyl, phenyl, phenyl 
substituted with J, phenyl disubstituted with J, 
phenyl trisubstituted with J, naphthyl, naphthyl 
substituted with J, naphthyl disubstituted with J, 
naphthyl trisubstituted with J, C1-6 alkyl with an 
attached phenyl group, C1-6 alkyl with two at-
tached phenyl groups, Ct-6 alkyl with an attached 
phenyl group substituted with J, or Ct-6 alkyl with 
two attached phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, Ct-6 al-
kyl-0-CO-NH-, or C1-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, or Ct-6 al-
kyl-0-CO-NH, Ct-6 alkyl-S-, or 
tosylamino, 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy, and 
wherein AA represents alanine, valine, leucine, iso-
leucine, methionine, phenylalanine, glycine, serine, 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
beta-alanine, norleucine, norvaline, phenylglycine, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, omithine or sarco-
sine. 
9. The · compound of claim 8, wherein AA is a 
blocked or unblocked amino acid. 
10. A compound of the formula: 
0 
R~~ 
~z 
y 
5,089,633 
28 27 
or a pharmaceutically acceptable salt thereof, wherein 
Z is selected from the group consisting ofC1-6alkoxy 
with a halogen attached to the alkoxy group, C1-6 
alkyl with a halogen attached to the alkyl group, 
C1-6 alkoxy with an attached C1-6 alkoxy group 5 
substituted with Q, 
wherein Q represents H, or C1-6 alkoxy, 
R is selected from the group consisting of OH, NH2, 
N02, O=C=N-, S==C=N-, M-NH-, 
M-0-, 10 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 15 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl sub-
stituted with K, phenyl, phenyl substituted with J, 
phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstitu- 20 
ted with J, C1-6 alkyl with an attached phenyl 
group, C1-6alkyl with two attached phenyl groups, 
C1-6 alkyl with an attached phenyl group substi-
tuted with J, or C1-6 alkyl with two attached 
phenyl groups substituted with J, 25 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 al-
kyl-0-CO-NH-, or C1-6 alkyl....:....S-, 
wherein K represents halogen, COOH, OH, CN, 30 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, or C1-6 al-
kyl-0-CO-NH-, C1-6 alkyl-S-, or 
tosylamino, and 
Y is selected from the group consisting ofH, halogen, 35 
trifluoromethyl, methyl, OH and methoxy. 
11. A compound of the formula: 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
40 
45 
Z is selected from the group consisting of C1-6 alkoxy 
with a halogen attached to the alkoxy group, C1-6 
alkyl with a halogen attached to the alkyl group, 50 
C1-6 alkoxy with an attached C1-6 alkoxy group 
substituted with Q, 
wherein Q represents H, or C1-6 alkoxy, 
R is selected from the group consisting of 
AA-NH-, M-AA-NH-, and M-AA-0-, 55 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 60 
C1-6 alkyl substituted with K, C1-6 fluoroalkyl sub-
65 
stituted with K, phenyl, phenyl substituted with J, 
phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstitu-
ted with J, C1-6 alkyl with an attached phenyl 
group, C1-6alkyl with two attached phenyl groups, 
C1-6 alkyl with an attached phenyl group substi-
tuted with J, or C1-6 alkyl with two attached 
phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 al-
kyl-0-CO-NH-, or C1-6 alkyl-S-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, or C1-6 al-
kyl-0-CO-NH-, C1-6 alkyl-S-, or 
tosylamino, 
Yis selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy, and 
wherein AA represents alanine, valine, leucine, iso-
leucine, methionine, phenylalanine, glycine, serine, 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
beta-alanine, norleucine, norvaline, phenylglycine, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrufline, hydroxyproline, omithine or sarco-
sine. 
12. The compound of claim 11, wherein AA is a 
blocked or unblocked amino acid. 
13. The compound of claim 10, wherein 
Z is selected from the group consisting of C1-6 alkoxy 
with a phenyl group attached to the C1-6 alkoxy, 
C1-6 alkyl with a phenyl group attached to the 
C1-6 alkyl, C1-6 alkoxy with an attached phenyl 
group substituted with J, C1-6 alkyl with an at-
tached phenyl group substituted with J, 
R is selected from the group consisting of OH, NH2, 
N02, O=C=N-, S==C=N-, M-NH-, 
M-0-. . 
14. The compound of claim 10, wherein 
Z is selected from the group consisting ofC1-6alkoxy 
with a phenyl group attached to the C1-6 alkoxy, 
C1-6 alkyl with a phenyl group attached to the 
C1-6 alkyl, C1-6 alkoxy with an attached phenyl 
group substituted with J, C1-6 alkyl with an at-
tached phenyl group substituted with J, 
R is selected from the group consisting of 
AA-NH-, M-AA-NH-, and M-AA-0-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, methionine, phenylalanine, glycine, serine, 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
beta-alanine, norleucine, norvaline, phenylglycine, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, omithine or sarco-
sine. 
15. The compound of claim 14, wherein AA is a 
blocked or unblocked amino acid. 
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